低分子肝素使用时机对关节置换手术失血量和DVT发生率的影响被引量：38

The effect of low molecular weight heparin on blood loss and incidence rates of DVT in total knee arthroplasty and total hip arthroplasty

原文传递

导出

摘要目的探讨全髋和全膝置换手术使用低分子肝素预防深静脉血栓（deepveinthrombosis，DVT）的时机对手术失血量和术后DVT发生率的影响。方法单侧初次关节置换262例中全髋关节置换179例，术前开始使用低分子肝素82例，术后开始使用97例；全膝关节置换83例，术前开始使用低分子肝素44例，术后开始使用39例。根据患者身高、体重及手术前后红细胞压积和输血量，计算两种给药时机的总失血量、隐性失血量及其占原血容量的比例，并比较DVT发生率。结果（1）全髋关节置换患者术前开始使用低分子肝素组总失血量平均为1638ml，占原血容量的38．1％；术后开始使用低分子肝素组1425ml，占原血容量的34-2％。全膝关节置换患者术前使用低分子肝素组1569ml，占原血容量的37．4％；术后开始使用低分子肝素组1319m1，占原血容量的31．6％。全髋和全膝置换术前开始使用与术后开始使用低分子肝素比较总失血量与其占原血容量比例的差异均有统计学意义。（2）全髋关节置换DVT的发生率为16．2％，全膝关节置换为25_3％，差异无统计学意义。结论术前使用低分子肝素可增加全髋和全膝关节置换手术的总失血量和隐性失血量，使用低分子肝素的时机对术后DVT的发生率无影响，术后再使用低分子肝素更安全。 Objective To explore the effect of low molecular weight heparin （LMWH） on blood loss and incidence rates of DVT in THA and TKA. Methods From April 2003 to December 2006, 179 patients underwent primary unilateral THA, including 67 males and 112 females with the average age of 68.4 years （range 46-78 years）. Using LMWH for 82 patients preoperatively, 97 patients postoperatively. 83 patients underwent TKA, including 31 males and 52 females with the average age of 65.2 years （range 55-76 years）. Using LMWH for 44 patients preoperatively and 39 patients postoperatively. The amount of total blood loss, the hidden blood loss and the rates of blood loss in the blood volume of patients were calculated. And the DVT incidence rates were compared between LMWH using timing. Results 1） In THA preoperatively LMWH using group, the average blood loss was 1638 ml, and 38.1% of the blood volume; while in postoperatively LMWH using group, the average blood loss was 1425 ml, and 34.2% of the blood volume. In TKA preoperatively LMWH using group, the average blood loss was 1569 ml, and 37.4% of the blood volume; while in postoperatively LMWH using group, the average blood loss was 1319 ml, and 31.6% of the blood volume. In THA and TKA group, there were significant differences between the preoperative and postopera- tive LMWH using groups in the amount of total blood loss, the rates of blood loss in the blood volume of pa- tients, and the hidden blood loss. However, there were no differences in the rates of hidden blood loss in the total blood loss. 2） The incidence rate of DVT was 16.2% in THA group, 25.3% in TKA group. Conclusion Preoperatively using LMWH can obviously increase the total blood loss and the hidden blood loss of THA and TKA. Preoperatively and postoperatively using LMWH have no differences in incidence rates of DVT. Postoperative initiate LMWH is safer than preoperative initiate LMWH on preventing DVT in THA and TKA.

作者马卫华张树栋慕宏杰王诗军毕海勇刘克贵赵中原

机构地区烟台市烟台山医院骨关节科

出处《中华骨科杂志》 CAS CSCD 北大核心 2008年第10期833-837,共5页 Chinese Journal of Orthopaedics

关键词肝素低分子量关节成形术置换失血手术静脉血栓形成 Heparin, low-molecular-weight Arthroplasty, replacement Blood loss, surgical Ve- nous thrombosis

分类号 R686 [医药卫生—骨科学]

引文网络
相关文献

参考文献20

1Rocha E, Imberti D, Paschina E. Low-molecular-weight heparins: before or after surgery? New concepts and evidence: congress report from the Sigma Tau/ROVI Satellite Symposium (Rome, Italy, 13 November 2006). Clin Drug Investig, 2007, 27: 357-366.
2Strebel N, Prins M, Agnelli G, et al. Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med, 2002, 162: 1451-1456.
3Nadler SB, Hidalgo JU, Bloch T. Prediction of blood volume in normal human adults. Surgery, 1962, 51: 224-232.
4Gross JB. Estimating allowable blood loss: corrected for dilution. Anesthesiology, 1983, 58:277-280.
5Planes A, Vochelle N, Fagola M. Total hip replacement and deep vein thrombosis: a venographic and necropsy study. J Bone Joint Surg (Br), 1990, 72: 9-13.
6Colwell CW Jr, Collis DK, Paulson R, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty: evaluation during hospitalization and three months after discharge. J Bone Joint Surg (Am), 1999, 81: 932-940.
7Fitzgerald RH Jr, Spiro TE, Trowbridge AA, et al. Prevention of venous thromboembolic disease following primary total knee arthroplasty: a randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. J Bone Joint Surg (Am), 2001, 83: 900-906.
8Lieberman JR, Hsu WK. Prevention of venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg (Am), 2005, 87: 2097-2112.
9Fiessinger JN. Huisman MV, Davidson BL. et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA, 2005, 293: 681-689.
10Choi BY, Huo MH. Venous thromboembolism following total knee replacement. J Surg Orthop Adv, 2007, 16: 31-35.

二级参考文献10

1赖红梅.全髋关节置换术患者术后并发症危险因素的评估及护理[J].解放军护理杂志,2004,21(8):45-46. 被引量：44
2Sehat KR,Evans R,Newman JH.How much blood is really lost in total knee arthroplasty? Correct blood loss management should take hidden loss into account.Knee,2000,7:151-155.
3Gross JB.Estimating allowable blood loss:corrected for dilution.Anesthesiology,1983,58:277-280.
4Ward CF,Meathe EA,Benumof JL,et al.A computer nomogram for blood loss replacement.Anesthesiology,1980,53:126-128.
5Nadler SB,Hidalgo JU,Bloch T.Prediction of blood volume in normal human adults.Surgery,1962,57:224-232.
6Newman JH,Bowers M,Murphy J.The clinical advantages of autologous transfusion:a randomized,controlled study after knee replacement.J Bone Joint Surg(Br),1997,79:630-632.
7Pattison E,Protheroe K,Pringle RM,et al.Reduction in haemoglobin after knee joint surgery.Ann Rheum Dis,1973,32:582-584.
8Faris PM,Ritter MA,Keating EM,et al.Unwashed filtered shed blood collected after knee and hip arthroplasties:a source of autologous red blood cells.J Bone Joint Surg(Am),1991,73:1169-1178.
9Erskine JG,Fraser C,Simpson R,et al.Blood loss with knee joint replacement.J R Coll Surg Edinb,1981,26:295-297.
10McManus KT,Velchik MG,Alavi A,et al.Non-invasive assessment of postoperative bleeding in TKA patients with Tc-99m RNCs.J Nuclear Med,1987,28:565-567.